What a year 2022 turned out to be! It was a year of growth and expansion, from the launch of our new KBI commercial manufacturing facility in Research Triangle Park (RTP), North Carolina, to the grand opening of our new mammalian-focused facility in...
Read More
The KBI Biopharma analytical facility in Leuven, Belgium, has received a successful inspection from Belgium’s regulatory authority, the Federal...
Durham, North Carolina (November 09, 2022) -- KBI Biopharma & Selexis (“KBI”) today announced the appointment of JSR Life Sciences President Tim...
KBI and Selexis welcome Abdelaziz Toumi, Ph.D., as Chief Business Officer. Toumi will lead Global Business Development for KBI and Selexis as well as...
The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel...
GENEVA, June 14, 2022— KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, announced today that an expanded, fully-integrated...
EXPANDS US-BASED MAMMALIAN CELL CULTURE OPERATIONS
KBI TO PRODUCE MATERIAL FOR USE IN FUTURE EXPECTED PHASE 2 CLINICAL TRIAL OF ORAGENICS’ INTRANASAL VACCINE CANDIDATE
KBI BIOPHARMA COMPLETES EUROFINS DISCOVERX PRODUCTS SPECIALIZED BIOASSAY CERTIFICATION PROGRAM Companies will work together on critical components...
Adalta Secures AD-214 Resupply Under KBI Biopharma MSA
